MPP Group

What MPP Group does

MPP Group LLC is a privately-held contract development and manufacturing organization (CDMO) headquartered in Mequon, Wisconsin, operating a 35,000-square-foot FDA-registered and cGMP-compliant pharmaceutical manufacturing facility. The company provides pharmaceutical-grade peptide manufacturing and drug delivery device development services to pharmaceutical and biotech customers, with a specialized focus on developing shelf-stable peptide formulations designed to maintain stability for up to 24 months. MPP Group is currently advancing a pipeline of 22 novel shelf-stable peptide formulations, 14 of which have been returned to FDA compounding eligibility. Founded in 2007, the company employs between 11 and 50 people and operates exclusively in the United States, serving clients in the broader $80.8 billion global peptide therapeutics market.

MPP Group's core differentiator is its proprietary shelf-stable peptide formulation technology, which addresses a key limitation in peptide therapeutics by reducing cold-chain requirements and extending product shelf life. The company combines this formulation capability with cGMP-compliant manufacturing infrastructure under FDA 21 CFR Part 11, providing integrated peptide API production and drug delivery device manufacturing from a single site. The equipment-funded partnership model allows clients to retain ownership of dedicated manufacturing equipment hosted within MPP's facility, avoiding approximately $6 million in capital expenditure per relationship and enabling faster entry into the peptide therapeutics market.

The company generates revenue through direct B2B contract manufacturing arrangements with pharmaceutical and biotech clients on a quote-based pricing model. Its go-to-market is relationship-driven rather than marketing-led, relying on industry networks and direct engagement with peptide therapeutics developers. In May 2026, MPP Group signed a three-year development and manufacturing agreement with Vector Science & Therapeutics covering peptide formulations and drug delivery devices, and separately entered into an agreement to be acquired by LyoGenesis Plus, a transaction that would consolidate MPP's manufacturing capabilities with Vector's equity-backed platform.

Name

MPP Group

Legal name

MPP Group LLC

Website

https://mppgroupllc.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

MPP Group LLC is a Wisconsin-based CDMO providing FDA-registered, cGMP-compliant peptide manufacturing and drug delivery device services to pharmaceutical and biotech clients, specializing in shelf-stable peptide formulations targeting the peptide therapeutics market.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (CDMO)

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Peptide manufacturing
• Contract pharmaceutical manufacturing
• Injectable drug development
• CGMP contract manufacturing
• Drug delivery device manufacturing

Headquarters

HQ city

Mequon

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Distribution channels1 record

Marketing channels1 record

Core offering

MPP Group LLC is a contract development and manufacturing organization (CDMO) that provides pharmaceutical-grade peptide manufacturing and drug delivery device development and manufacturing services from its FDA-registered, cGMP-compliant 35,000-square-foot facility in Mequon, Wisconsin. The company supports pharmaceutical and biotech clients in producing shelf-stable peptide formulations with up to 24 months of stability, targeting the global peptide therapeutics market.

Product overview

MPP Group LLC operates as a contract development and manufacturing organization (CDMO) offering pharmaceutical-grade peptide manufacturing and drug delivery device development/manufacturing services. The company operates a 35,000-square-foot FDA-registered, cGMP-compliant facility in Mequon, Wisconsin. Their service portfolio includes manufacturing 22 novel shelf-stable peptide formulations designed to remain stable for up to 24 months, supporting Vector Science & Therapeutics' entry into the $80.8 billion peptide therapeutics market.

Differentiator

Problem solved

Functional benefit

Products and services

• Peptide Manufacturing Services

Quantifiable outcome

• 22 novel shelf-stable peptide formulations in development pipeline
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• LyoGenesis PluscoreStrategic or Co-development Partner · 14 May 2026LyoGenesis Plus has entered into an agreement to acquire MPP Group LLC, an FDA-registered and cGMP-compliant contract manufacturing company. This acquisition would give Vector Science & Therapeutics (through its equity interest in LyoGenesis Plus) long-term access to pharmaceutical-grade manufacturing infrastructure for developing shelf-stable peptide formulations targeting the $80.8 billion peptide market.
• Vector Science & TherapeuticscoreStrategic or Co-development Partner · 11 May 2026Three-year development and manufacturing agreement between Vector Science & Therapeutics and MPP Group LLC for pharmaceutical-grade peptide and drug delivery device development and manufacturing. Vector funds and retains ownership of dedicated manufacturing equipment while MPP provides access to its FDA-registered cGMP-compliant facility in Mequon, Wisconsin. The partnership supports development of 22 novel shelf-stable peptide formulations targeting the $80.8 billion peptide therapeutics market, with formulation development commencing May 2026.

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• AmbioPharm: US-based peptide CDMO offering custom peptide synthesis, GMP manufacturing, and formulation development. Direct competitor in the niche peptide CDMO space MPP addresses.
• CPC Scientific: Peptide-focused CDMO providing custom peptide synthesis and GMP manufacturing services to pharmaceutical and biotech clients. Directly competes with MPP in the same service category.
• Bachem: Swiss-based global leader in peptide CDMO services, including custom synthesis, GMP manufacturing, and formulation. Directly comparable to MPP as a peptide-focused CDMO serving pharma and biotech, but at vastly larger scale.
• PolyPeptide Group: Specialty CDMO focused exclusively on peptide and oligonucleotide API manufacturing for pharma and biotech. Closely comparable business model and customer base to MPP, with broader GMP capacity and global footprint.

Broad incumbents

• Lonza: Global, diversified CDMO with a sizable peptide and small-molecule API offering. Competes with MPP in peptide manufacturing but as part of a much broader portfolio across biologics, cell and gene, and small molecules.
• CordenPharma: CDMOs and offers peptide API manufacturing (formerly Peptisyntha) among its broader service lines including injectables and small molecules. Comparable peptide manufacturing capability to MPP within a larger diversified CDMO platform.
• Cambrex: Small-molecule API and finished dosage CDMO with peptide capabilities, serving pharma customers from cGMP facilities. Comparable cGMP manufacturing positioning but with broader scale than MPP.
• WuXi AppTec: Large global CRO/CDMO providing peptide synthesis and GMP manufacturing among its extensive service portfolio. Competes with MPP for biotech outsourcing dollars, though not peptide-exclusive.

Emerging players

• Bachem Holding (American Peptide Company): Smaller peptide manufacturers and emerging CDMOs building cGMP capacity targeting the same niche biotech customers MPP serves, often with specialized formulation or stability differentiation.
• Scorpius BioManufacturing: Emerging CDMO offering biomanufacturing and fill-finish services; competes for outsourced pharma manufacturing demand though more biologics-focused than MPP's peptide specialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/MPPGroupLLC
• LinkedInlinkedin.com/company/mpp-group-llc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MPP Group